Ablation

Pulsed Field Ablation (PFA) Market to Surge at a Stunning 40% CAGR: Revolutionizing Cardiac Ablation and Beyond - ResearchAndMarkets.com

Retrieved on: 
Tuesday, October 24, 2023
Biotechnology, Health, Cardiology, Medical Devices, Ageing, Compound annual growth rate, Arrhythmia, Prevalence, Atrial fibrillation, PFA, Skin, Tissue, Growth, Risk, Safety, Pain, Apoptosis, Diagnosis, Key (company), Medical imaging, Ablation

The Pulsed Field Ablation (PFA) market, a rapidly expanding segment within the cardiac ablation sector, is set to witness robust growth with a projected Compound Annual Growth Rate (CAGR) of approximately 40% during the forecast period of 2023-2035.

Key Points: 
  • The Pulsed Field Ablation (PFA) market, a rapidly expanding segment within the cardiac ablation sector, is set to witness robust growth with a projected Compound Annual Growth Rate (CAGR) of approximately 40% during the forecast period of 2023-2035.
  • However, conventional ablation methods primarily rely on thermal energy, which can lead to tissue overheating and post-procedural pain.
  • Enter pulsed field ablation (PFA), a game-changing approach harnessing high-voltage electrical pulses delivered in short bursts.
  • The Pulsed Field Ablation Market: Distribution by Therapeutic Area, Product Components, Application Areas, Source of Ablation, and Key Geographical Regions report for 2023-2035 provides a comprehensive overview of this rapidly evolving medical devices segment.

Cardiology Applications Drive Dominance in the Radiofrequency Ablation Devices Market, Fueled by Rising Cardiovascular Disease Prevalence - ResearchAndMarkets.com

Retrieved on: 
Thursday, October 19, 2023
Health, Cardiology, United States Census Bureau, Ventricular tachycardia, Neoplasm, Patient, Asset, Ageing, Incidence, Radiofrequency ablation, Arrhythmia, Abdominal ultrasonography, Mortality, Prevalence, Cardiovascular disease, Conditional sentence, Atrial fibrillation, Ablation, Vels Institute of Science, Technology & Advanced Studies, Death, Liver cancer, World Health Organization, Risk, Radio frequency, Cancer, Hospital, Wilford Hall Ambulatory Surgical Center, Center for Economic Studies (U.S. Census Bureau), Osteoporosis, Traction, USD, Safety, Arthritis, Pharmaceutical industry, Medical imaging, Dietary supplement, Health care, Growth

The increasing prevalence of chronic diseases, especially cardiovascular diseases and cancers, coupled with a growing elderly population and technological innovations in these devices, is fueling the demand for radiofrequency ablation devices.

Key Points: 
  • The increasing prevalence of chronic diseases, especially cardiovascular diseases and cancers, coupled with a growing elderly population and technological innovations in these devices, is fueling the demand for radiofrequency ablation devices.
  • Cardiovascular Diseases: A major cause of global mortality, driving the demand for radiofrequency ablation devices.
  • The escalating incidence of cardiovascular diseases is expected to drive the demand for radiofrequency ablation devices, especially in the treatment of atrial fibrillation.
  • Radiofrequency ablation devices are widely used in oncology and cardiology to treat conditions such as tumors and arrhythmias.

My Cardiologist Welcomes New Physicians for Enhanced Care

Retrieved on: 
Thursday, September 28, 2023
Hypertension, Ablation, Coronary artery disease, Cardiology, Heart failure, Patient, Arrhythmia, Pharmaceutical industry, Medical imaging, Medical device

These highly trained, board-certified cardiologists bring a wealth of expertise in various cardiology subspecialties, bolstering My Cardiologist's mission to provide top-tier, comprehensive heart care.

Key Points: 
  • These highly trained, board-certified cardiologists bring a wealth of expertise in various cardiology subspecialties, bolstering My Cardiologist's mission to provide top-tier, comprehensive heart care.
  • Dr. Jonathan Greenblatt : A highly trained noninvasive cardiologist with expertise in hypertension management, cardiovascular imaging, and preventive cardiology.
  • “This significant expansion of the My Cardiologist team underscores the organization's commitment to providing top-notch cardiovascular care to our patients," said Dr. Harry Aldrich, President of My Cardiologist.
  • With this expanded team, My Cardiologist reaffirms its commitment to delivering exceptional cardiovascular care to the communities it serves.

IceCure Medical to Join Hands-On Cryoablation Session with ProSense and Host Symposium Led by Renowned Doctors at the CIRCE 2023 Annual Congress

Retrieved on: 
Friday, September 8, 2023
ENT, Endometriosis, CE, Abstract, IR, Plantar fibromatosis, Travel, Ablation, Cryoablation, Q&A, Neoplasm, Woman, Breast, CIRSE, Doctor of Philosophy, Lung, Congress, CHU, Traction, Freezing, Circulatory system, Cardiovascular and Interventional Radiological Society of Europe, Kidney, Liver, Malignancy, LN2, Medical imaging, Management, MD

IceCure will exhibit ProSense and provide hands-on demonstrations at booth #D56.

Key Points: 
  • IceCure will exhibit ProSense and provide hands-on demonstrations at booth #D56.
  • IceCure will be participating in the Tumor Ablation Hands-On Device Training with the ProSense cryoablation system.
  • This is a great opportunity for attendees to gain hands-on knowledge of IceCure's cryoablation device and to see the system's advantages.
  • Thanks to this grant, ten aspiring women interventional radiologists' abstracts were accepted and will receive sponsored congress registration, travel, and accommodation.

Techsomed Announces FDA Clearance for Ablation Treatment Planning and Confirmation Software

Retrieved on: 
Tuesday, September 5, 2023
CT, University, IO, Ablation, 3D, Liver tumor, De novo transcriptome assembly, Doctor of Philosophy, MRI, Magnetic resonance imaging, MD, Patient, Physician, Risk, Visual control, AI, FDA, Recurrence, Food, Safety, Medical device, Medical imaging

REHOVOT, Israel, Sept. 5, 2023 /PRNewswire/ -- Techsomed Ltd., a medical software innovator dedicated to enhancing clinical impact in ablation therapy, announced today that it has received 510(k) clearance from the USA Food and Drug Administration (FDA) for its VisAble.IO software intended to assist physicians in planning liver ablation procedures, and confirming ablation zones, with the goal of increasing treatment precision.

Key Points: 
  • REHOVOT, Israel, Sept. 5, 2023 /PRNewswire/ -- Techsomed Ltd., a medical software innovator dedicated to enhancing clinical impact in ablation therapy, announced today that it has received 510(k) clearance from the USA Food and Drug Administration (FDA) for its VisAble.IO software intended to assist physicians in planning liver ablation procedures, and confirming ablation zones, with the goal of increasing treatment precision.
  • Ablation Therapy is a preferred minimally invasive treatment that uses extremely high or low temperatures to destroy abnormal tissue.
  • VisAble.IO employs advanced computation and image registration to assist physicians in crucial steps of planning and assessing the ablation coverage of liver tumor.
  • This is a pivotal step forward in our journey of elevating ablation therapy into image guided ablation therapy and making it available for every patient everywhere".

Global Oncology Devices Research Report 2023: Enhanced Treatment Options Propels Growth - Analysis by Device Type (Ablation, Embolization), & Cancer Type (Breast, Uterine, Colon and Rectum, Prostate) - ResearchAndMarkets.com

Retrieved on: 
Thursday, August 31, 2023
Health, Oncology, Medical Devices, Research report, Surgery, Value, Breast cancer, Radiation, Cancer, Ageing, Prostate, Ablation, USD, Incidence, Uterine cancer, Colon, Patient, Application, Prostate cancer, SCSI Peripheral Device Type, Protocol on Mines, Booby-Traps and Other Devices, PET/CT, Disease, Diagnosis, Mortality, Biopsy, Medical imaging, Speciality chemicals, Rectum, Embolization, Select, Breast

The Global Oncology Devices Market is expected to generate 217.00 billion by the end of 2029, up from USD 69.80 Billion in 2022.

Key Points: 
  • The Global Oncology Devices Market is expected to generate 217.00 billion by the end of 2029, up from USD 69.80 Billion in 2022.
  • During the forecast period, 2024-2029, the Global Oncology Devices market is expected to grow at a CAGR of 18.05%.
  • The oncology devices market is comprised of a vast assortment of medical devices used for the detection, treatment, and management of cancer.
  • PET/CT price in Select countries, In EUR
    Global Oncology Devices Market Segmentation: By Device Type
    Global Oncology Devices Market Size, By Ablation Devices, By Value, 2019H-2029F (USD Billion & CAGR)
    Global Oncology Devices Market Size, By Embolization devices, By Value, 2019H-2029F (USD Billion & CAGR)
    Global Oncology Devices Market Size, By Other Devices, By Value, 2019H-2029F (USD Billion & CAGR)
    Global Oncology Devices Market Segmentation: By Cancer Type
    Global Oncology Devices Market Size, By Breast cancer, By Value, 2019H-2029F (USD Billion & CAGR)
    Global Oncology Devices Market Size, By Uterine cancer, By Value, 2019H-2029F (USD Billion & CAGR)
    Global Oncology Devices Market Size, By Colon and rectum cancer, By Value, 2019H-2029F (USD Billion & CAGR)
    Global Oncology Devices Market Size, By Prostate cancer, By Value, 2019H-2029F (USD Billion & CAGR)
    Global Oncology Devices Market Size, By Other Cancer Types, By Value, 2019H-2029F (USD Billion & CAGR)
    Global Oncology Devices Market Segmentation: By Application
    Global Oncology Devices Market Size, By Chemotherapy, By Value, 2019H-2029F (USD Billion & CAGR)
    Global Oncology Devices Market Size, By Radiation, By Value, 2019H-2029F (USD Billion & CAGR)
    Global Oncology Devices Market Size, By Surgical, By Value, 2019H-2029F (USD Billion & CAGR)
    Global Oncology Devices Market Size, By Diagnosis, By Value, 2019H-2029F (USD Billion & CAGR)

BioSig Introduces New Subscription Model for PURE EP™ Platform, Offering Quicker Access to Latest Features, Customizations

Retrieved on: 
Wednesday, August 23, 2023
Heart Rhythm Society, Cleveland Clinic, Clinic, Exhibition, HRS, Nation, U.S. News & World Report, Research, History, Ablation, Physician, Electrophysiology, Nautilus, Inc. v. Biosig Instruments, Inc., Cardiology, Arrhythmia, News, PURE, Software, Pharmaceutical industry

Cleveland Clinic—recently ranked as number one in the Nation for cardiology, heart & vascular surgery by U.S. News & World Report1—is first to sign an agreement to acquire the PURE EP™ Platform under the subscription model.

Key Points: 
  • Cleveland Clinic—recently ranked as number one in the Nation for cardiology, heart & vascular surgery by U.S. News & World Report1—is first to sign an agreement to acquire the PURE EP™ Platform under the subscription model.
  • BioSig has made the move to a subscription model so that electrophysiologists and cardiology departments can access the latest features with the ability to customize the rich suite of PURE EP™ software capabilities to suit their needs.
  • During the conference, research conceptualized and spearheaded by Cleveland Clinic’s world-class physician faculty highlighted the PURE EP™ Platform’s ability to optimize ablation procedures.
  • For more information on how PURE EP™ can enhance arrhythmia identification and laboratory workflows, visit BioSig.com .

AngioDynamics Completes Enrollment for PRESERVE Clinical Study

Retrieved on: 
Thursday, August 3, 2023
Science, Cardiology, Research, Oncology, General Health, Health, Medical Devices, Clinical Trials, Society, IRE, Partnership, University, Bureau of Oceans and International Environmental and Scientific Affairs, University of Michigan, British Association of Urological Surgeons, Cancer, Quality of life, Ablation, Irreversible electroporation, Death, Incidence, Nanoknife, Regeneration, MD, Patient, Memorial Sloan Kettering Cancer Center, American Cancer Society, Disease, Prostate cancer, Medical imaging

The PRESERVE study was initiated by AngioDynamics, Inc. in partnership with the Society of Urologic Oncology Clinical Trials Consortium (SUO-CTC).

Key Points: 
  • The PRESERVE study was initiated by AngioDynamics, Inc. in partnership with the Society of Urologic Oncology Clinical Trials Consortium (SUO-CTC).
  • "The PRESERVE study demonstrates AngioDynamics’ commitment to innovating care delivery,” said Juan Carlos Serna, AngioDynamics Senior Vice President of Clinical and Scientific Affairs.
  • We appreciate the support provided by our PRESERVE study sites and the partnership with the SUO-CTC team in this important effort.”
    Final patient enrollment in the study was initially announced during AngioDynamics’ Fiscal 2023 Fourth Quarter and Full-Year Financial Results conference call on July 12, 2023.
  • The PRESERVE study will have its primary endpoint analysis at 12 months following treatment.

NanOlogy Presents Clinical Research at 2023 DDW and ASCO Involving its Large Surface Area Microparticle Investigational Drugs

Retrieved on: 
Wednesday, June 7, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Docetaxel, Ohio State University, Radiation, LSAM, Intraductal papillary mucinous neoplasm, Ohio State University Wexner Medical Center, Cyst, Clinical trial, Research, SOC, Doctor of Philosophy, ASCO, DDW, Patient, Risk, Ablation, Toxic epidermal necrolysis, Pancreatic cyst, Safety, Pharmaceutical industry, MD

NanOlogy LLC , a clinical-stage oncology company, announces a presentation of clinical research involving its large surface area microparticle (LSAM) investigational drugs at DDW 2023 in May and publication at ASCO Annual Meeting in June.

Key Points: 
  • NanOlogy LLC , a clinical-stage oncology company, announces a presentation of clinical research involving its large surface area microparticle (LSAM) investigational drugs at DDW 2023 in May and publication at ASCO Annual Meeting in June.
  • The DDW poster entitled “Intracystic Injection of Large Surface Area Microparticle Paclitaxel (LSAM-PTX) for Chemoablation of Intraductal Papillary Mucinous Neoplasms: Insights from an Expanded Access Protocol,” was presented by the research team of Somashekar Krishna, MD of The Ohio State University Wexner Medical Center.
  • The expanded access protocol prospectively evaluated safety and response of six subjects from the trial who received additional doses of LSAM-PTX.
  • “In this protocol, intracystic LSAM-PTX was safe and resulted in cyst volume and surface area reduction, morphological changes, and loss of pathogenic mutations,” said Dr. Krishna.

New Data at Heart Rhythm 2023 Suggests that Unipolar Signals May be Used for a More Precise, Accurate Approach to Treating Arrhythmias

Retrieved on: 
Friday, May 19, 2023
Abstract, Cardiac electrophysiology, PURE, Cleveland Clinic, PVI, Atrial fibrillation, Stroke, 3D, OH, New product development, Cardiac muscle, Radiofrequency ablation, EGM, MBA, Ablation, Conductor, Hospital, Heart Rhythm, MD, Physician, Risk, Electrophysiology, Arrhythmia, Cleveland, FDA, Pig, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Medical imaging, Medical device

Across all three studies, researchers compared the efficacy of using unipolar signals to guide procedures to the current standard of using an Ablation Index™.

Key Points: 
  • Across all three studies, researchers compared the efficacy of using unipolar signals to guide procedures to the current standard of using an Ablation Index™.
  • "These studies suggest that the preservation of raw cardiac signal enables the use of unipolar signals to help guide ablations, while improving lesion precision and reducing procedure time."
  • The PURE EP™ engineering enables physicians to access the value of unipolar radiofrequency guidance, established by previous studies.
  • A single gap was left in the linear application of the fifth model due to a misinterpretation of the unipolar EGM during pacing.